EGFR and non-small cell lung carcinoma: An increasing number of reports have shown that NSCLC patients with EGFR gene mutations (EGFR+) tend to have more central nervous system (CNS) metastases, including both brain and leptomeningeal metastases after using of EGFR‐tyrosine kinase inhibitors (TKIs) in association with theuse of EGFR‐tyrosine kinase inhibitors (TKIs).